Dr. James Son, MD
What this data tells you about Dr. Son
Dr. James Son is a rheumatology specialist in Cranberry Township, PA, with 10 years of NPI registration. Based on federal Medicare data, Dr. Son performed 59,593 Medicare services across 666 unique beneficiaries.
Between the years covered by Open Payments, Dr. Son received a total of $39,751 from 18 pharmaceutical and/or device companies across 115 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are classified as research and scientific activities (grants and research funding). Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Son is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Tocilizumab injection (Actemra) | 39,540 | $5 | $11 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
10,200 | $11 | $20 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
7,025 | $34 | $46 |
| Denosumab injection (Prolia/Xgeva) | 1,560 | $18 | $25 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
367 | $136 | $201 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
330 | $96 | $141 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
287 | $112 | $151 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
104 | $129 | $180 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
77 | $63 | $80 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
71 | $24 | $31 |
| Limited ultrasound of joint or extremity A focused ultrasound exam of a specific joint or other structure in the arm or leg, excluding blood vessels. |
17 | $36 | $50 |
| New patient office visit, complex (60-74 min) | 15 | $184 | $251 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
All-time payments by company (2019-2024) ›
Associated products mentioned in payments ›
The majority of payments (93%) are classified as scientific/research, suggesting involvement in clinical studies, grants, or innovation-related work.
Geographic Context
6.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Son is a mixed practice specialist, with above-average Medicare volume (top 21% in PA), with research-focused industry engagement in the top 13% of PA peers.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Son experienced with tocilizumab injection (actemra)?
Does Dr. Son receive payments from pharmaceutical companies?
How do Dr. Son's costs compare to other rheumatologists in Cranberry Township?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology